Protein inhibitor of activated STAT3 modulates osteoclastogenesis by down-regulation of NFATc1 and osteoclast-associated receptor

被引:47
作者
Kim, Kabsun
Lee, Junwon
Kim, Jung Ha
Jin, Hye Mi
Zhou, Bin
Lee, Soo Young
Kim, Nacksung
机构
[1] Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Kwangju, South Korea
[2] Res Inst Med Sci, Kwangju, South Korea
[3] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA
[4] Ewha Womans Univ, Div Mol Life Sci, Seoul, South Korea
[5] Ewha Womans Univ, Ctr Cell Signaling Res, Seoul, South Korea
关键词
D O I
10.4049/jimmunol.178.9.5588
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Protein inhibitor of activated STAT3 (PIAS3) has been shown to regulate the activity of various transcription factors. In this study, we show that the overexpression of PIAS3 in bone marrow-derived monocyte/macrophage lineage cells attenuates osteoclast formation and down-regulates the expression of NFATc1 and osteoclast-associated receptor (OSCAR), which are important modulators in osteoclastogenesis. PIAS3 has been shown to associate with histone deacetylase 1 as well as with transcription factors, including the microphthalmia transcription factor, NFATc1, and c-Fos. Moreover, overexpression of PIAS3 inhibits the transactivation of target genes such as NFATc1 and OSCAR. This inhibitory effect of PIAS3 is possibly mediated by histone deacetylase 1 recruitment to the promoter regions of NFATc1 and OSCAR. Furthermore, silencing of PIAS3 by RNA interference in osteoclast precursors enhances osteoclast formation as well as gene expression of NFATc1 and OSCAR. Taken together, our results reveal that PIAS3 acts as a modulator in osteoclastogenesis.
引用
收藏
页码:5588 / 5594
页数:7
相关论文
共 40 条
  • [1] Osteoclast differentiation and activation
    Boyle, WJ
    Simonet, WS
    Lacey, DL
    [J]. NATURE, 2003, 423 (6937) : 337 - 342
  • [2] Specific inhibition of Stat3 signal transduction by PIAS3
    Chung, CD
    Liao, JY
    Liu, B
    Rao, XP
    Jay, P
    Berta, P
    Shuai, K
    [J]. SCIENCE, 1997, 278 (5344) : 1803 - 1805
  • [3] SUMO protein modification
    Dohmen, RJ
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1695 (1-3): : 113 - 131
  • [4] THE ULTRASTRUCTURE OF OSTEOCLASTS IN MICROPHTHALMIC MICE
    HOLTROP, ME
    COX, KA
    EILON, G
    SIMMONS, HA
    RAISZ, LG
    [J]. METABOLIC BONE DISEASE & RELATED RESEARCH, 1981, 3 (02): : 123 - 129
  • [5] IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro
    Horwood, NJ
    Elliott, J
    Martin, TJ
    Gillespie, MT
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (08) : 4915 - 4921
  • [6] Involvement of FcRγ in signal transduction of osteoclast-associated receptor (OSCAR)
    Ishikawa, S
    Arase, N
    Suenaga, T
    Saita, Y
    Noda, M
    Kuriyama, T
    Arase, H
    Saito, T
    [J]. INTERNATIONAL IMMUNOLOGY, 2004, 16 (07) : 1019 - 1025
  • [7] A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases
    Jackson, PK
    [J]. GENES & DEVELOPMENT, 2001, 15 (23) : 3053 - 3058
  • [8] Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis
    Kim, K
    Kim, JH
    Lee, J
    Jin, HM
    Lee, SH
    Fisher, DE
    Kook, H
    Kim, KK
    Choi, YW
    Kim, NS
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (42) : 35209 - 35216
  • [9] KIM K, 2006, IN PRESS BLOOD
  • [10] A novel member of the leukocyte receptor complex regulates osteoclast differentiation
    Kim, N
    Takami, M
    Rho, J
    Josien, R
    Choi, Y
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (02) : 201 - 209